40106-58-9Relevant academic research and scientific papers
Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor
Fyfe, Tim J.,Kellam, Barrie,Mistry, Shailesh N.,Scammells, Peter J.,Lane, J. Robert,Capuano, Ben
, p. 474 - 490 (2019/03/07)
We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D2 receptor (D2R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D2R including NAMs with sub-μM affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).
Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile
Mghwary, Aml E.-S.,Gedawy, Ehab M.,Kamal, Aliaa M.,Abuel-Maaty, Suzan M.
, p. 838 - 852 (2019/04/04)
Aim: Design and synthesis of thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors.Material and methods: A series of novel 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine derivatives with different substituents on C-4 position was synthesized and evaluated for their anticancer activity against MCF-7 cell line. EGFR, VEGFR-2 inhibitory assay, the cell cycle analysis and apoptosis induction ability of the most potent compound 5f were evaluated.Results: Most of the compounds showed moderate to significant anticancer activity. Compound 5f exhibited the most potent anticancer activity being 1.73- and 4.64-folds more potent than erlotinib and doxorubicin, respectively. Compound 5f showed potent EGFR inhibitory activity being 1.18-folds more potent than reference standard erlotinib and it also showed good VEGFR-2 inhibitory activity at the micromolar level with IC50 value 1.23?μM. Compound 5f caused induction of cell cycle arrest at G2/M phase and accumulation of cells in pre-G1 phase. Compound 5f induced cellular apoptosis.
Identification of 4-methoxythieno[2,3-d]pyrimidines as FGFR1 inhibitors
Balanda, A. O.,Bdzhola, V. G.,Kotey, I. M.,Pletnova, L. V.,Protopopov, M. V.,Prykhod’ko, A. O.,Starosyla, S. A.,Yarmoluk, S. M.
, p. 152 - 162 (2020/06/02)
Aim. To identify novel FGFR1 inhibitors using virtual screening approach. Methods. We used methods of organic synthesis, molecular docking via the Autodock 4.2.6 program package and in vitro biochemical tests with γ-32P. Results. In vitro experiments showed that 9 of 23 tested compounds possess inhibitory activity against FGFR1 with IC50 values in the range from 0.9 to 5.6 μM. Conclusions. Nine FGFR1 inhibitors were developed. The mode of compounds binding with the ATP-acceptor site was determined using molecular docking methods and the dependence of the compounds’ activity on the substituents R1, R4 and R5 was evaluated.
Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors
El-Sharkawy, Lina Y.,El-Sakhawy, Rowaida A.,Abdel-Halim, Mohammad,Lee, Kevin,Piazza, Gary A.,Ducho, Christian,Hartmann, Rolf W.,Abadi, Ashraf H.
, (2018/04/20)
Novel cycloalkene-fused thienopyrimidine analogues with enhanced phosphodiesterase 5 (PDE5) inhibitory properties are presented. The structure of the reported scaffold was modulated through variation of the terminal cycloalkene ring size, as well as by va
Design, Synthesis, and Biological Evaluation of Some Cyclohepta[b]Thiophene and Substituted Pentahydrocycloheptathieno[2,3-d]Pyrimidine Derivatives
Elmongy, Elshaymaa I.,Khedr, Mohammed A.,Taleb, Nageh A.,Awad, Hanem M.,Abbas, Safinaz E.-S.
, p. 1084 - 1093 (2017/03/27)
This investigation describes the design of a series of cycloheptathieno[2,3-d]pyrimidines along with their synthetic strategy. The target compounds were screened for their PARP-1 inhibitory activity. The modeling study declared that most of the docked compounds showed the same interactions as 3-aminobenzamide, where Gly 894, His 862, Tyr 896, Arg 878, and Ser 864 were the main residues involved in hydrogen bond formation. Compounds eliciting the top ranked docking results were screened for their PARP-1 inhibitory activity giving promising results, and three representative compounds were tested for their cytotoxic activity using Doxorubicin as a reference standard. The target compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 including cyclohepta[b]thiophene and pentahydrocycloheptathieno[2,3-d]pyrimidine cores were designed, prepared, and tested for their PARP-1 inhibitory activity. Compounds 16 (R: ―NHC(S)NH2) and 11 (R: ―C S) were the most potent ones.
C-C (alkynylation) vs C-O (ether) bond formation under Pd/C-Cu catalysis: Synthesis and pharmacological evaluation of 4-alkynylthieno[2,3-d]pyrimidines
Gorja, Dhilli Rao,Shiva Kumar,Mukkanti,Pal, Manojit
, p. 338 - 345 (2011/06/18)
The Pd/C-CuI-PPh3 catalytic system facilitated C-C bond formation between 4-chlorothieno[2,3-d]pyrimidines and terminal alkynes in methanol with high selectivity without generating any significant side products arising from C-O bond formation b
Studies with polyfunctionality substituted heterocycles: Novel syntheses of thienopyrimido-1,2,4-triazoles
El-Gazzar,Hegab,Swelam,Aly
, p. 123 - 136 (2007/10/03)
Several 3-substituted-(un)-cyclohepta(b)thieno[2,3-d]pyrimido[3,4-a]-1,2,4-triazoles 10, 11, 12, 13, and 14 were prepared by reaction of an appropriate substituted 2-amino-3-cyanothiophene 1 with aliphatic acids or benzoyl chloride. Also the fusion of 1 with urea, thiourea to give the corresponding 2-oxo or thioxo-4-aminopyrimidine derivatives 6a, b and other reactions of compound 1 are reported.
